Estrella Immunopharma Inc (ESLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,797 | -4,421 | -470 | -2,891 | -1,871 |
| Accounts payable and accrued liabilities | -72 | -77 | -77 | -9,256 | 5 |
| Other Working Capital | 1,054 | -106 | -3,765 | -9,846 | 401 |
| Other Operating Activity | 72 | 77 | 77 | 10,451 | 1,190 |
| Operating Cash Flow | $-6,744 | $-4,526 | $-4,235 | $-11,542 | $-275 |
| Cash Flows From Investing Activities | |||||
| Other Investing Activity | 0 | 0 | 0 | 4,961 | -112 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $4,961 | $-112 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 300 | 300 |
| Debt Repayment | N/A | N/A | N/A | -5,073 | N/A |
| Common Stock Repurchased | -505 | -354 | -84 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | 17,921 | 19,746 |
| Financing Cash Flow | $-505 | $-354 | $-84 | $13,148 | $20,046 |
| Beginning Cash Position | 9,046 | 9,046 | 9,046 | 2,479 | 2,479 |
| End Cash Position | 1,798 | 4,165 | 4,727 | 9,046 | 22,138 |
| Net Cash Flow | $-7,249 | $-4,881 | $-4,319 | $6,567 | $19,659 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,744 | -4,526 | -4,235 | -11,542 | -275 |
| Free Cash Flow | -6,744 | -4,526 | -4,235 | -11,542 | -275 |